JPM vs MBX Stock Comparison
MBX currently leads JPM in this stock comparison, with AIQ scores of 68 vs 65. The clearest difference is balanced, while JPM has the stronger risk resilience profile.
What is the main difference between JPM and MBX?
MBX leads the current stock comparison as MBX Biosciences, Inc. Common Stock, with the clearest separation coming from balanced and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
JPMorgan Chase & Co. vs MBX Biosciences, Inc. Common Stock
MBX leads
MBX leads by 3 AIQ points.
Fragile: 2 of 5 evidence groups support MBX, and its signal state is cleanly positive.
JPMorgan Chase & Co.
MBX Biosciences, Inc. Common Stock
The Algovestiq AIQ Score currently favors MBX over JPM, 68 versus 65 as of Nov 15, 2026. MBX also shows the weaker technical structure relative to its 50-day moving average. 2 of 5 covered evidence groups favor MBX today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 3 points. MBX lead: Stable — the AIQ differential has held near 3 points over 30 sessions.
Compare JPMorgan Chase & Co. and MBX Biosciences, Inc. Common Stock across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Total return with distributions reinvested, from daily closes.
Total return comparison
Growth of $10,000, distributions reinvested
Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.
Compare JPM and MBX against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Risk Resilience87 vs 50JPM +37
- Quality86 vs 74JPM +12
- Momentum70 vs 71Even
2 of 5 evidence groups favor MBX. Neither name separates cleanly on the covered dimensions.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Momentum +1, not enough on its own to move the overall score.
New signals
- Drawdown Recovery Signal — bullish, risk_regime, long horizon (-9.0%)
- MACD Histogram Expanding Bullish — bullish, momentum, short horizon
Largest factor move: Momentum +3
New signals
- Accumulation Pattern — bullish, volume, medium horizon (1.59x)
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- MACD Histogram Expanding Bullish — bullish, momentum, short horizon
MBX's lead widened by 1 AIQ point in the latest session.
Deeper signal detail for each name lives on its own signals page — JPM and MBX both carry a full feed there.
The central trade-off
MBX (MBX Biosciences, Inc. Common Stock): the stronger current systematic profile.
JPM (JPMorgan Chase & Co.): the counter-case, on risk resilience, quality, fundamentals.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
MBXMBX on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
JPMJPM on combined revenue and EPS growth.
Value
EvenThe two are level on Value.
Momentum
EvenThe two are level on Momentum.
Lower downside
JPMJPM on Risk Resilience, by 37 points.
Analyst upside
MBXMBX on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | JPM | MBX | Note |
|---|---|---|---|
| Implied upside to target | +7.8% | +90.7% | MBX has more room |
| Target dispersion | +30.3% | +61.9% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 26 | 12 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
2 of 5 covered evidence groups favor MBX. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | Even | 65 vs 68 |
| Fundamentals | JPM | EPS growth -27.6% vs -65.4%; TTM ROE 4.1% vs -13.2% |
| Valuation | Not covered | Not covered |
| Technicals | MBX | Price vs 50-day 1.7% vs 0.3%; vs 200-day 6.6% vs 20.8% |
| Risk Resilience | JPM | Risk Resilience 87 vs 50 |
| Analyst expectations | MBX | Target upside 7.8% vs 90.7% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of JPM and MBX and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is narrow at 3 points. (argues the conclusion is provisional)
- Only 2 of 5 covered evidence groups agree. (argues the conclusion is provisional)
- The lead has been steady session to session. (supports the conclusion holding)
- The leader's signal state is cleanly positive. (supports the conclusion holding)
- Analyst targets on the leader are widely dispersed. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on MBX.
How the comparison changed
120 daily snapshots · May 27 – Nov 13MBX lead: Stable — the AIQ differential has held near 3 points over 30 sessions.
- Today
- MBX +3
- 65 vs 68
- 7 sessions ago
- MBX +3
- 64 vs 67
- 30 sessions ago
- MBX +5
- 63 vs 68
- 90 sessions ago
- MBX +11
- 64 vs 75
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
6 bullish / 1 bearish / 1 neutral, conflicted
Only JPM
- Bollinger Band Squeeze — neutral, volatility, short horizon (5.9%)
- Drawdown Recovery Signal — bullish, risk_regime, long horizon (-9.0%)
- Low Volume Rally Warning — bearish, volume, short horizon (0.65x)
- TRIX Bullish Signal — bullish, momentum, short horizon
7 bullish / 0 bearish / 2 neutral
Only MBX
- ADX Trend Weakening — neutral, trend, medium horizon
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (6.79%)
- Accumulation Pattern — bullish, volume, medium horizon (1.59x)
- Price Reclaimed 50-Day MA — bullish, trend, medium horizon
- TSI Bullish Crossover — bullish, momentum, short horizon
Both carry 4 more signals that do not separate them: Golden Cross Active, EMA Ribbon Expansion Bullish, MACD Histogram Expanding Bullish, Uptrend Structure Active.
JPM is conflicted, so the timing case there is weaker than the score alone suggests.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.98%, AIQ 0 points).
Price and the AIQ Score both moved up over the latest session (price +2.62%, AIQ +1 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1JPM's Bollinger Band Squeeze turns directional — it is neutral today and would confirm a change in trend.
- 2MBX's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict.
- 3A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
JPM leads on balance| Metric | JPM | MBX |
|---|---|---|
| Revenue growth (YoY) | -7.6% | 0% |
| EPS growth (YoY) | -27.6% | -65.4% |
| Gross margin | 63.2% | 0% |
| Operating margin | 28.2% | 0% |
| Return on equity (TTM) | 4.1% | -13.2% |
| Debt to equity | 3.32 | 0.01 |
Performance
MBX leads 5 of 6 windows| Metric | JPM | MBX |
|---|---|---|
| 1 week (5 sessions) | 3.5% | 8.9% |
| 1 month (20 sessions) | 1.9% | 12.8% |
| 3 months (63 sessions) | -4.1% | -18% |
| 6 months (126 sessions) | 16.2% | 72.4% |
| Year to date | 7.4% | 77.4% |
| 1 year (252 sessions) | 8% | 127.4% |
Technicals
MBX has the stronger structure| Metric | JPM | MBX |
|---|---|---|
| RSI (14) | 56.1 | 53.3 |
| ADX (14) | 18 | 13.7 |
| Price vs 50-day | 1.7% | 0.3% |
| Price vs 200-day | 6.6% | 20.8% |
| Volatility (1M, annualized) | 27.4% | 68.2% |
Risk
JPM is the more resilient| Metric | JPM | MBX |
|---|---|---|
| Beta | 0.78 | 1.26 |
| Sharpe ratio | 0.44 | 1.42 |
| Sortino ratio | 0.61 | 2.43 |
| Max drawdown | -15.5% | -37.6% |
| Current drawdown | -5.2% | -20.9% |
| Annualized volatility | 22.7% | 77.3% |
| Value at risk (95%) | -2.4% | -7.1% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, JPM or MBX?
On the Algovestiq AIQ Score, MBX is the stronger of the two as of Nov 15, 2026, scoring 68 against JPM's 65. The edge comes from its factor profile. JPM is not without a case — it holds the better risk resilience profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is JPM or MBX the better buy right now?
MBX carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Fragile — 2 of 5 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 3 points. Treat the lead as provisional.
Why does the AIQ Score favor MBX over JPM?
The composite weights Quality, Value, Momentum and Risk Resilience. JPM leads Risk Resilience by 37 points; JPM leads Quality by 12 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, JPM or MBX?
Analyst price targets imply +7.8% upside for JPM and +90.7% for MBX, so the Street currently favors MBX. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, JPM or MBX?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, JPM or MBX?
JPM on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, JPM or MBX?
The two are level on Momentum. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, JPM or MBX?
JPM is the more resilient of the two, so the other name carries the higher downside risk. JPM on Risk Resilience, by 37 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is JPM more profitable than MBX?
JPM leads on the comparable margin measures — gross margin 63.2% vs 0%; operating margin 28.2% vs 0%; ttm roe 4.1% vs -13.2%.
Is MBX's lead over JPM getting stronger or weaker?
MBX lead: Stable — the AIQ differential has held near 3 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.
What would change the JPM vs MBX verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: JPM's Bollinger Band Squeeze turns directional — it is neutral today and would confirm a change in trend; MBX's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about JPM and MBX?
JPM: 6 bullish / 1 bearish / 1 neutral, conflicted. MBX: 7 bullish / 0 bearish / 2 neutral. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on JPM is Golden Cross Active (bullish, long horizon). On MBX it is Golden Cross Active (bullish, long horizon).
Compare JPM and MBX with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.